AUG 13·SEC EDGARLow
Stevens Christopher James sold $128K of RCKT
Stevens Christopher James (Chief Operating Officer) sold 36,658 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.50 ($0.13M total) on 2026-08-11.
StockNASDAQ · US · USDHealthcare · Biotechnology
$RCKT
ROCKET PHARMACEUTICALS, INC.
Price · $RCKTvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $145K 2 txs
Chaudhuri Sarbani1× · $16K
10b5-1 share of filings0%
Top stories · $RCKTMore →
AUG 10·SEC EDGAR 8-K
ROCKET PHARMACEUTICALS, INC. (RCKT): Results of Operations and Financial Condition
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20079821_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress All three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined
AUG 4·yahoo.com
Rocket points to Danon gene therapy’s safety after Phase II protocol change
Rocket Pharmaceuticals said its RP-A501 Danon disease gene therapy has safely treated three Phase II patients after an FDA-triggered protocol change. The FDA allowed relaunch of NCT06092034 in Aug 2025. Rocket reports no capillary leak syndrome, blood vessel damage, or other serious adverse events since dosing with a recalibrated dose plus rituximab, sirolimus, and corticosteroids.
RCKT sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning RCKT (ROCKET PHARMACEUTICALS, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent RCKT coverage spans financial news, insider activity and technology.
In the last 30 days, RCKT insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($145K). The most active reporter was Chaudhuri Sarbani, See Remarks, with 1 filing.
What's driving RCKT
The filing is a routine insider sale with no stated 10b5-1 plan, but it does not by itself change fundamentals.
Near-term trading focus is on FDA path-to-pivotal updates for Danon disease and cash runway, with additional catalysts tied to PKP2-ACM and BAG3-DCM trial progress.
Early post-amendment safety appears to de-risk the pivotal relaunch, improving odds of completing the Phase II program and supporting a future approval path.
Early patient-level safety confirmation after a prior clinical hold reduces near-term binary risk for RP-A501, supporting sentiment into the Aug 6 earnings date.
Management/finance leadership transition is a governance and reporting-control signal, but the filing provides no new financial guidance or operational change.
alphai scores every news story that mentions RCKT with an AI model for sentiment and relevance, and aggregates insider trades from ROCKET PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $RCKT
Score
Stevens Christopher James sold $128K of RCKT
Stevens Christopher James (Chief Operating Officer) sold 36,658 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.50 ($0.13M total) on 2026-08-11.
2 min readROCKET PHARMACEUTICALS, INC. (RCKT): Results of Operations and Financial Condition
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20079821_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress All three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined
6 min readRocket points to Danon gene therapy’s safety after Phase II protocol change
Rocket Pharmaceuticals said its RP-A501 Danon disease gene therapy has safely treated three Phase II patients after an FDA-triggered protocol change. The FDA allowed relaunch of NCT06092034 in Aug 2025. Rocket reports no capillary leak syndrome, blood vessel damage, or other serious adverse events since dosing with a recalibrated dose plus rituximab, sirolimus, and corticosteroids.
5 min readWhy is Rocket Pharmaceuticals stock volatile today?
Investing.com reports Rocket Pharmaceuticals (RCKT) rose 0.6% pre-open after it said the first three patients treated under a revised Phase 2 protocol for RP-A501 Danon disease gene therapy showed no significant safety issues, including no thrombotic microangiopathy or capillary leak syndrome. The FDA lifted the clinical hold in mid-2025. Shares were $3.13 ahead of Aug 6 Q2 2026 earnings.
3 min readROCKET PHARMACEUTICALS, INC. (RCKT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001281895 0001281895 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2026 R
2 min readROCKET PHARMACEUTICALS, INC. (RCKT): Completion of Acquisition or Disposition of Assets
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001281895 0001281895 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2026 R
2 min readShah Gaurav sold $172K of RCKT
Shah Gaurav (CEO) sold 55,684 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.09 ($0.17M total) on 2026-05-21.
1 min read
Rocket Pharmaceuticals Shareholders Approve 2026 Governance Proposals
Rocket Pharmaceuticals (RCKT) recently held its 2026 Annual Meeting of Stockholders, where shareholders re-elected the full slate of seven directors and ratified EisnerAmper LLP as the independent registered accounting firm. Investors also approved executive compensation and a stock option exchange program, signaling support for governance continuity and talent retention. While TipRanks' AI Analyst "Spark" rates RCKT as Neutral due to weak financials, the company benefits from strong corporate catalysts like FDA accelerated approval and significant non-dilutive funding.
4 min readWedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances
Wedbush Securities has reiterated its "outperform" rating for Rocket Pharmaceuticals, citing the company's progress in its cardiac gene therapy pipeline. The broker believes the stock is significantly undervalued, maintaining a $16 price target against the current trading price of $4.97. Key advancements include the resumption of patient dosing for its Phase 2 Danon disease study and the upcoming Phase 1 trial for RP-A701 targeting BAG3-dilated cardiomyopathy.
4 min readTwo Launches in Two Days from Two Hemispheres: Rocket Lab Beats Annual Launch Record with Back-To-Back Electron Missions
Rocket Lab today completed its second launch in two days from its launch sites in two hemispheres, setting a new annual launch record for the Company.
3 min read